| Projects must investigate biomarkers that measure pathology of the disease, e.g., imaging biomarkers, tissue biopsy derived biomarkers, fluid biomarkers, and genetic biomarkers (somatic mutations, SNPs, epigenetics and gene products).<\/p>\n Biomarkers should be novel, and have strong preliminary data to justify testing in human samples\/data and\/or cohorts. Applications focused on Abeta, tau or alpha-synuclein are discouraged unless there is an aspect of the work that is particularly novel.<\/p>\n Biomarkers must be under development for human disease diagnosis, prognosis (including rate of progression), stratification to clinical trials, measuring disease progression, and\/or to predict or measure response to therapy (e.g., a surrogate for clinical endpoint).<\/p>\n <\/p>\n Biomarker discovery and unbiased screening approaches are not eligible for this program.<\/td>\n<\/tr>\n |